Laurus Labs Q2 net profit surges on 33% rise in revenue
Laurus is executing a transformation strategy and operationalised its first commercial scale peptide plant in Visakhapatnam to address surging demand for peptide therapeutics.
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Updated - October 29, 2026 08:56 pm IST - HYDERABAD
Laurus said it is acquiring 60% stake in Galenvs Sciences Inc., a contract research and development organisation based in Montreal. | Photo Credit: The Hindu
Pharmaceutical and biotechnology company Laurus Labs reported a more than twofold increase in consolidated net profit to ₹436.74 crore for the September quarter, driven by a 33% growth in revenue from operations.
Revenue from operations rose to ₹2,206.37 crore from ₹1,653.47 crore in the corresponding quarter last year, supported by contributions from the contract development and manufacturing organisation (CDMO) business, particularly small molecules, and the Affordable Medicine division.
The company also declared an interim dividend of ₹1 per equity share of ₹2 face value.
Laurus said it is acquiring 60% stake in Galenvs Sciences Inc., a contract research and development organisation based in Montreal, Canada, at a pre-money valuation of $3.50 million.
The company proposes to invest $3.75 million comprising a primary infusion of $2.75 million and a secondary acquisition of $1 million.
Galenvs specialises in custom oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) technologies for the diagnostics and therapeutics markets.
The Board of Laurus on Thursday also approved acquisition of 52% in Hyderabad-based SI & C Resins at a pre-money valuation of ₹30 crore.
Laurus proposes to invest a total of ₹32.50 crore, by way of primary acquisition of 10,833 equity shares, equivalent to 52% of post-issue equity capital in the company that specialises in manufacturing and supply of high-quality polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries.
On the quarterly performance, founder and CEO Satyanarayana Chava said it demonstrates the strength of the company’s CDMO platform and Affordable Medicines portfolio.
Laurus is executing a transformation strategy and operationalised its first commercial scale peptide plant in Visakhapatnam to address surging demand for peptide therapeutics.
It has made investments in Oligonucleotides and peptide-resins technologies, he said.
business (general) / pharmaceutical / medicine / earnings / merger, acquisition and takeover / foreign investment
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
